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Abstract
Background—When the case-only study design is used to estimate statistical interaction
between genetic (G) and environmental (E) exposures, G and E must be independent in the
underlying population, or the case-only estimate of interaction (COR) will be biased. Few studies
have examined the occurrence of G-E association in published control group data.
Methods—To examine the assumption of G-E independence in empirical data, we conducted a
systematic review and meta-analysis of G-E associations in controls for frequently investigated
DNA repair genes (XRCC1 Arg399Gln, Arg194Trp, or Arg280His, XPD Lys751Gln, and
Asp312Asn, and XRCC3 Thr241Met) and smoking (ever/never smoking, current/not current
smoker, smoking duration, smoking intensity and pack-years).
Results—Across the 55 included studies, SNP-smoking associations in controls (ORz) were not
reliably at the null value of 1.0 for any SNP-smoking combinations. Two G-E combinations were
too heterogeneous for summary estimates: XRCC1 399 and ever-never smoking (N=21), and XPD
751 and pack-years (N=12). ORz ranges for these combinations were: [ORz (95% confidence
interval (CI)] 0.7 (0.4, 1.2) – 1.9 (1.2, 2.8) and 0.8 (0.5, 1.3) – 2.3 (0.8, 6.1), respectively).
Estimates for studies considered homogeneous (Cochran’s Q p-value <0.10) varied 2- to 5-fold.
No study characteristics were identified that could explain heterogeneity.
Conclusions—We recommend the independence assumption be evaluated in the population
underlying any potential case-only study, rather than in a proxy control group(s) or pooled
controls.
Impact—These results suggest that G-E association in controls may be population-specific.
Increased access to control data would improve evaluation of the independence assumption.
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The case-only study design as proposed by Prentice et. al (1) and promoted by Piegorsch et.
al. (2) has been increasingly used to estimate the magnitude of statistical interaction between
two measured exposures with respect to a given outcome, most commonly a genetic and an
environmental exposure. This method requires only cases, no controls or defined cohort.
Provided the relevant exposures are independent in the underlying source population, the
case-only study can estimate a specific form of statistical interaction, but not main effects of
the two exposures.
There are potential advantages to the case-only method in several settings. Estimation of the
interaction parameter from case-only analyses is more efficient than for a traditional case-
control study (i.e. fewer cases are required for similar precision of estimate) and with no
need for controls, there are fewer participants overall (3). Not using controls may mitigate
selection biases due to, for example, differential recruiting success between cases and
controls, or differential recall of environmental exposures by case-control status. Invasive
procedures that are part of cases’ diagnosis or treatment often cannot be done ethically in
healthy volunteers, especially vulnerable groups such as pediatric populations (4). But these
advantages come at a cost. A case-only study only estimates interaction on a multiplicative
scale (deviation of the rate ratio for those having both the genetic and environmental
exposures from the product of rate ratios for those with either the genetic or the
environmental exposure, but not both). It cannot estimate the independent effect of either
exposure, or interaction on the additive scale. This limits its use to situations in which the
independent effects of the two exposures are not of interest, nor are synergism or
antagonism of the exposures (5–6). Control-selection bias is the only validity threat the case-
only design avoids, in comparison with the case-control design. Consequently, case-only
studies have been proposed by several investigators as an initial screening method to
identify candidate gene-environment or gene-gene interactions (7–9).
However, the increase in precision and avoidance of control-selection bias in the case-only
method requires a major assumption: that the two exposures are independent in the source
population (Z=1) (1–2). Although the constancy of rate ratios between different strata of
exposure in the underlying source population is the true parameter of interest, control groups
from case-control studies are frequently used to estimate Z using ORz. Data simulations
have demonstrated that even when violations of the independence assumption are of small
magnitude they can strongly bias the case-only interaction parameter (7). Chance can also
play a role. Since the expectation that ORz=1 when Z=1 is a large sample asymptotic
approximation, as sample size decreases, ORz will deviate from the null with increasing
frequency through random error alone (7). Further, when control-group gene-environment
(G-E) associations are of similar magnitude but opposite in direction to the interaction
effect, a case-only study may not detect interaction effects, a Type II error (7,10).
However, published control group data on the associations of interest for G×E interaction
research are limited. Therefore, we undertook a systematic review and meta-analysis of
selected DNA repair gene polymorphisms in XRCC1, XPD and XRCC3 and smoking
behavior in control groups, using ORz to estimate Z. The purpose in estimating ORz was to
determine the degree of bias in the COR, relative to the interaction estimate from a case-
control analysis, assuming no control-selection bias. Heterogeneity was explored using
stratified analysis and meta-regression of study characteristics. The primary aim of this
project was to evaluate the independence assumption for selected SNPs and smoking
behavior. This will enable investigators considering a stand-alone case-only study of gene-
environment interaction with these exposures to evaluate the independence assumption more
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PubMed, ISI Web of Science and the CDC Genomics and Disease Prevention databases
were searched up to March 6, 2007 for peer-reviewed literature likely to contain non-case
data on the joint distribution of any of the polymorphisms of interest. Polymorphisms of
interest were non-synonymous single nucleotide changes (SNPs) in XRCC1[Arg399Gln
(rs25487), Arg194Trp (rs1799782), and Arg280His (rs25489)], XPD [Asp312Asn
(rs1799793) and Lys751Gln (rs13181)], and XRCC3 [Thr241Met (rs861539)] (11–15).
Non-case groups were defined as any group not selected on disease status (e.g. cohorts,
convenience samples and control groups from case-control studies). For simplification non-
case groups will be referred to as controls throughout this article. There were no language
restrictions on searches. A list of keywords for PubMed and the ISI Web of Science was
developed in consultation with an information specialist from UNC Health Science Library
to ensure that searches would be as inclusive as possible. Keywords for smoking were
“smoking”, “tobacco”, “tobacco smoke”, “tobacco smoke pollution”, and “smoker”. The
SNPs were searched by combining “polymorphism” and “polymorphism, genetic” with the
SNP-specific keywords “XRCC1”, “XPD”, "xeroderma pigmentosum group d protein",
“ERCC2” and “XRCC3”. ISI Web of Science keywords were “smok*” and “tobacco,” and
“XRCC1”, “XPD”, “ERCC2” and “XRCC3”. GDPInfo was searched by limiting by factor
menu terms to “smoking behavior”, “smoking (tobacco) passive”, “smoking (tobacco) bidi”,
“smoking (tobacco)”, “smoking (tobacco) maternal”, “tobacco”, “indoor air pollution”,
“nicotine (nasal spray)”, and “nicotine (transdermal)”, and gene menu terms to “XRCC1”,
“XPD”, “ERCC2” and “XRCC3”.
Inclusion criteria were deliberately broad. To be included, an article had to contain original
control group data on the joint distribution of any genotype of interest and any aspect of
tobacco smoking behavior. Abstracts were excluded.
Abstracts were screened for controls with relevant genotype and smoking data. SNP
designations considered equivalent are shown in Table 1. If an abstract passed the initial
screening, the full paper was reviewed for data appropriate for construction of a 2×2 table
for genotype-smoking association in controls (ORz). If a genotype-smoking ORz could be
calculated, the following data were abstracted: SNP, genotype categories (3 level additive,
dominant and/or recessive models), smoking status and dose categories [ever/never, current/
not current, smoker/non-smoker, ever/former/current, pack-years (PY), duration and/or
intensity], and cell counts for all genotype and smoking categories.
The following study characteristics were also abstracted: year of publication, study design
(case-control, cohort, cross-sectional, convenience, other), source of control group (for case-
control: population, hospital, friends and non-blood related family, convenience,
community, neighborhood, other; for cohorts: population, occupational, convenience, other),
type of clinic that hospital- or clinic-based control groups were from (disease clinics,
checkup clinics), study outcome (cancer [type], non-cancer disease, non-disease), full study/
control group size (N), country, percent male participants, ethnicity, Hardy Weinberg
equilibrium p-value, full study/control group size (N), and minor allele frequency (MAF).
An estimate of central tendency for participants’ age in years (“average age”) was derived
for each study using, in order of preference: median, mean, weighted average across study
categories, midpoint of range. One non-English language article could not be evaluated.
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Selection of Study Comparisons
No study population contributed to any analysis more than once, maintaining independence
of observations. Analyses focused on associations with genotype categorized using a
dominant model (i.e. homozygotes of the most common allele were the referent group,
compared to heterozygotes plus homozygotes of the minor allele) due to the small number
of studies that provided sufficient information to assess recessive or additive models. The
minor allele did not vary across studies for any of the included SNPs. Smoking status was
categorized as (1) ever/never (referent), and (2) current/not current (referent). Smoking
amount was analyzed as (1) pack-years [PY, highest vs. lowest non-zero category
(referent)], (2) duration [years, longest vs. shortest non-zero category (referent)] and (3)
smoking intensity [cigarettes/day, heaviest vs. lightest non-zero category (referent)].
Studies that did not provide sufficient data to include ‘passive only’ smoking in the never
smoking group were excluded. For analyses of current/not current smoking, never+former
smokers and “non-smokers” (unless identified as never smokers) were considered not
current smokers. Pack-years of smoking (PY = pack-years = number of packs smoked per
day multiplied by years smoked; 20 cigarettes=1 pack) were collected as categorical
variables with different cutpoints. We analyzed PY as relative categories [heaviest vs.
lightest smokers regardless of PY cutpoints] and absolute categories [high PY (all categories
with a cutpoint above a specified minimum) vs. low PY (all categories with a cutpoint below
a specified maximum)]. The minimum and maximum cutpoints varied by SNP but were all
chosen to maximize the number of included studies while keeping the range of cutpoints
small enough that no study would have >1 cutpoint between the minimum and maximum
cutpoints. Similar to PY, smoking intensity was categorized by relative (heaviest vs. lightest
smokers regardless of cigarette/day cutpoints) and absolute (>= 20 vs. <20 cigarettes/day)
measures. The smoking duration cutpoints were 20 and 40 years, inclusive, for all SNPs.
Statistical analyses
Crude ORs and 95% confidence limits were calculated from cell counts (Stata 9.2, using
metan STB-44: sbe24). Funnel plot asymmetry, an indicator of possible publication bias
(16), was considered suggestive of study characteristics associated with variance and Z.
When data were sufficient (Nstudies>=5), asymmetry was formally assessed using Begg and
Mazumdar’s test (17) and Egger’s test (18) at α=0.10. Cochran’s Q two-sided homogeneity
p-values (α=0.10 due to low power of the test) were used to assess overall heterogeneity in
odds ratios (19).
Study characteristic analyses—Key study characteristics hypothesized to influence
variation in the strength of control group SNP-smoking associations across studies were
assessed using stratified meta-analysis and random-effects meta-regression, with the among-
study variance estimated by restricted maximum likelihood (20). Stratified meta-analysis
produces a summary ORz estimate for each stratum of a study characteristic. Meta-
regression provides a formal comparison of the stratified estimates in the form of an
estimated ratio of odds ratios.
Study characteristics were selected a priori. They included (1) study design (case-control,
cohort, or convenience; patient-based control groups, healthy control groups), (2) continent,
(3) ethnicity, (4) Hardy-Weinberg equilibrium p-value, (5) average age, (6) gender (%
male), (7) study outcome (lung cancer, other cancer, non-cancer disease, non-disease), (8)
minor allele frequency and (9) smoking prevalence. Study design was examined for all SNP-
smoking combinations; additional study characteristics were examined for XRCC1 399,
XPD 751 and XRCC3 241. Stratified random-effects meta-analyses were used when the
overall SNP-smoking association had a Cochran’s Q p-value α<0.10, otherwise fixed effects
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meta-analysis was used, regardless of the homogeneity p-values of individual strata. To
reduce the possibility of results being confounded by ethnicity (population stratification) in
overall analyses and when examining the study characteristics likely to vary strongly by
ethnicity (Hardy Weinberg equilibrium p-values and minor allele frequency) studies were
stratified by ethnicity and treated as separate studies if possible. Sample size was not
formally examined as a study characteristic because that would have essentially reproduced
funnel plot analyses of variance. Variance (or precision) is the more important measure here,
and sample size is not the sole determinant of precision. However, because the independence
assumption is a large sample approximation, a sensitivity analysis was conducted in which
large (N>=1000) studies were examined separately. Stata 9.2 was used for all analyses.




The literature searches identified 228 articles for evaluation. Of these, 55 articles were
eligible for inclusion. The primary reason for exclusion was that an article did not present
the genotype-smoking distribution in controls (N=98, 57% of exclusions). Exclusion reasons
for the remainder included: review article or abstract only (13%), did not assess any relevant
SNPs (9%), and did not have any non-cases (10%). Finally, of the 55 studies eligible for
inclusion, five were not included in final summary estimates because no data were presented
using the dominant genetic model (21–22), there was no measure of adult smoking behavior
(23), former smokers were excluded (24), or never smokers were included in lowest PY
category (25). Fifty articles representing 46 distinct study populations were included in the
final meta-analyses (brief study descriptions in Supplementary Table 1). The number of
study populations included for each polymorphism was: XRCC1 Arg399Gln (N=32),
XRCC1 Arg194Trp (N=16), XRCC1 Arg280His (N=8), XPD Lys751Gln (N=16), XPD
Asp312Asn (N=9), and XRCC3 Arg241Gln (N=13). Thirty-seven studies presented the
control distribution of genotype and ever/never smoking, 16 for current/ not current smoking
and 14 for PY. Far fewer presented duration (N=4) and/or intensity (N=4). Case-control
studies predominated with 12 population-based (26–37) and 23 hospital-based (38–60), four
studies nested within cohorts (61–64) and two other case-control studies (65–66). Most
control groups were from cancer case-control studies (N=39), one was from a case-control
study of rheumatoid arthritis. Nine cohort or convenience sample studies examined non-
cancer outcomes, predominantly measures of DNA damage (67–75).
Association between DNA repair gene variants and smoking behavior
Across SNPs there was more variation in ORs assessing control-only G-E associations
(ORzs) for measures of smoking amount (PY, duration, intensity) than for measures of
smoking status (ever-never, current-not current) (Table 2). Ten of 11 summary estimates of
smoking status fell between 0.9–1.1. Summary estimates for smoking amounts were
distributed more broadly, with only five of 10 summary estimates between 0.9–1.1; the most
extreme measures were found for duration and intensity. Although only two of 18 genotype-
smoking groups were too heterogeneous for a fixed effects summary estimate, based on
Cochran’s Q at alpha=0.10, nearly all groups had study estimates above and below the null.
Individual study ORz (95% CI) are presented in Figure 1 and Supplementary Tables 3–8.
For XRCC1 399 any Gln and ever-never smoking, ORzs ranged from 0.7 (95% CI: 0.3, 1.7)
(49) to 1.9 (95% CI: 1.0, 3.7) (34) (See Figure 1); three other measures of smoking behavior
were homogeneous enough for a summary estimate of ORz: current smoker/not current
(N=11), PY (N=9) and intensity (N=4) (Table 2). Higher PY and heavier smoking intensity,
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but not current vs. not current smoking, were associated with XRCC1 Arg399Gln (any Gln)
[OR (95%CI): 1.2 (1.0, 1.5) and 1.5(1.2, 1.9), respectively]. For XRCC1 194 and 280,
having the variant allele was associated with smoking duration [XRCC1 194: 0.7 (0.5, 0.9),
XRCC1 280: 1.2 (0.6, 2.3)] and current smoking [XRCC1 280: 1.2 (0.6, 2.3)] though the
number of studies was small. For the two XPD SNPs (751, 312) there was considerable
variation in the association between XPD 751 variant allele and higher PY. Study estimates
ranged from 1.4 (0.8, 2.6) (41) to 0.5 (0.3, 1.0) (53) (Table 2). Higher PY were associated
with the variant allele for XRCC3 241 although the number of studies was small (N=4).
Sensitivity analyses
Among the studies that were assessed for current-not current smoking, a subset could also be
assessed for never, former or current smoking (Supplementary Table 2). No consistent
pattern emerged for comparisons of never smoking with former or current smoking.
Absolute measures of PY, intensity and duration were calculated and compared to relative
measures for consistency. Genotype-PY estimates for absolute cutpoints were comparable to
estimates using relative categories although strata were sparse (Supplementary Table 2).
Additionally, when studies with only smokers were dropped and never smoking was used as
the reference category, results were essentially the same for relative and absolute measures
of PY.
Genotype-smoking association between XRCC1 Arg399Gln and smoking intensity
(cigarettes/day) could be estimated in four studies. There was an association between
XRCC1 399 any Gln and greater smoking intensity, which was consistent across methods of
smoking intensity categorization. Results did not change appreciably when studies without
smoking amount were excluded from ever-never analyses, indicating that articles that
presented dose were not driving estimates of smoking status. Results did not change
appreciably when studies without smoking amount were excluded from ever-never analyses,
indicating that articles that presented dose were not driving estimates of smoking status (data
not shown).
There were six large (N>=1000) study populations, four each with data for XRCC1 399 &
194 ever-never smoking. ORzs for XRCC1 399 ever-never smoking showed evidence of
heterogeneity [range of ORz(95% CI): 1.0(0.8, 1.2) – 1.6(1.2, 2.0)] (Supplementary Table 3)
(32, 35, 42, 60). However, ORzs for XRCC1 194 were consistently null across studies
(Supplementary Table 4)(32, 37, 42, 61). In the three large study populations with the
relevant measures of smoking,(32, 42, 60) the magnitude of ORz was consistently different
for status and amount for XRCC1 399 ever-never smoking; the one study population with
smoking status and amount for XRCC1 194 had ORzs at the null.(42) Data were too sparse
for further evaluation across large studies.
Funnel plot asymmetry
There was no evidence of funnel plot asymmetry for overall genotype-smoking associations
(data not shown). In formal testing, the majority of p-values (75%) were >=0.3; the lowest
p-value was p=0.14.
Study characteristics
Stratified associations and univariate meta-regression were evaluated across SNPs and
smoking categories on the basis of consistency and direction. Study design was examined
for all six SNPs for ever/never, current/not current smoking and PY. For smoking status,
genotype-smoking associations for XRCC1 399 and 194 and XPD 751 and 312 were
generally stronger for population-based case-control studies than for hospital-based or
patient-based control groups, although the magnitude of the differences was small; the range
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of RORs was 0.7 to 0.9 for hospital/patient-based compared to population-based controls
(referent) (Table 3). However, for smoking amount as measured by PY (2 evaluable SNPS,
XRCC1 399 and XPD 751) the hospital-based/patient-based control groups showed stronger
genotype-smoking associations than population-based control groups (range of RORs: 1.2–
1.5). When examining PY, for all SNPs, the genotype-smoking association for population-
based control groups was below the null. The remaining study characteristics were examined
only for XRCC1 399, XPD 751 and XRCC3 241 (Tables 4, 5, and 6 respectively) due to
sparse data for the other SNPs.
For PY, lung cancer studies were above the null for all three SNPs. When compared to
studies of other cancers the genotype-smoking association was stronger for lung cancer
studies (referent) compared to other cancer studies [ROR= 0.8(0.5, 1.2) and 0.5(0.3, 0.9) for
XRCC1 399 and XPD 751, respectively]. All studies with PY were cancer studies. Older
average age of study participants weakly but consistently showed stronger associations
between ever smoking and variant allele for XRCC1 399, XPD 751 and XRCC3 241 than did
younger age. For XRCC1 399 only, this was evident across all three smoking categories.
Also, for XRCC1 399 current-not current smokers and PY only, studies with lower minor
allele frequencies (N=3) showed stronger associations (~2.0) than those with higher MAF.
These three studies had only African-American or Asian participants. No strong and/or
consistent patterns emerged for other study characteristics examined.
Discussion
This systematic review and meta-analysis of DNA repair genotypes and smoking behavior
in control data was conducted with the goal of examining the independence assumption of
case-only studies of gene-environment interaction. There was considerable variation in
estimates of Z for XRCC1 399 ever-never smoking and XPD 751 PY of smoking. Point
estimates of ORz varied as much as 5-fold, even when studies were homogeneous enough
for a summary estimate. Summary estimates for individual SNPs varied across smoking
categorizations, with larger magnitudes of association generally found for measures of
smoking dose (PY, intensity, duration) than for smoking status (ever-never, current-not
current). There was a weak association between XRCC1 399 and higher smoking dose (PY,
intensity). No study characteristics examined strongly predicted the magnitude of
association although study outcome (lung cancer vs. other cancer for PY), study design
(population-based vs. hospital/patient-based), and age warrant further investigation.
Although the validity of case-only estimates rests on the independence assumption (2,65),
literature on independence assumption verification is limited. Data simulations have
demonstrated that small violations of the independence assumption can strongly bias the
case-only interaction parameter (7). Even an ORz of 1.2 biased the COR by nearly 30%.
Further, when Z ≠ 1 in population subgroups, the COR for those subgroups will be biased as
well.
However, little empirical work has been conducted to quantitatively assess the magnitude of
control-only associations (ORz) between DNA repair gene variations and smoking. A
population-based study (N=339) of Japanese males assessed association between ‘habitual
smoking’ (ever/never) and a panel of 153 SNPs in 40 candidate genes, including the DNA
repair genes OGG1 and NUDT1(MTH1) (66). Association was found between smoking and
3 of 4 of the SNPs in OGG1 (0.4–0.6, borderline statistical significance).
Smoking amount (PY and/or intensity) may be causally associated with variation in XRCC1
399, or with a polymorphism in linkage disequilibrium with XRCC1 399. There is evidence
that the XRCC1 399 and XPD 751 variants are functional (67–69). Different aspects of
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smoking behavior (smoking initiation, smoking cessation, intensity etc.) operate through
multiple overlapping pathways (70) therefore would not be expected to be identically
affected by DNA repair variation. This is supported by the differing results for smoking
status and amount for several SNPs (XRCC1 399, XRCC1 280, XPD 751, XRCC3 241).
There is some evidence that variation in DNA repair activity may affect neurological and/or
respiratory outcomes, which could in turn affect smoking behavior (71–75). If the variants
are functional, or linked to functional variants, heterogeneity could be due to gene-
environment interaction in specific populations.
There are also several possible non-causal explanations for these finding. Although
publication bias is a concern with meta-analyses, visual inspection of funnel plots and
formal tests of asymmetry argue against this. Spurious results for XRCC1 399 and smoking
amount could be caused by selection bias in a subsample of studies. Just over half of the
studies with smoking amount information for XRCC1 399 were lung cancer studies (8 of 14)
and lung cancer studies had on average higher ORzs than other cancer studies for all PY
analyses. The connection between smoking and lung cancer is well known, possibly leading
to more variation in response rates or recall by smoking history and/or family history of
cancer, but the direction of possible bias is unpredictable. The ORz for the one XRCC1 399
study that explicitly excluded participants with smoking-related diseases was essentially the
same as the summary estimate (42).
Population stratification could have contributed to the heterogeneity in XRCC1 399 ever-
never and XPD 751 PY estimates since the variant alleles are found at different frequencies
in different ethnic groups within the same study, and smoking behavior may also differ by
ethnicity. Although this cannot be rigorously assessed without individual level data, there
were no clear patterns in ORz for any SNP for study-level ethnicity, either by stated
ethnicity, when stratified by single-ethnicity vs. multi-ethnicity studies, or when MAF was
used as a crude proxy to assign ethnicity for studies with unknown ethnic makeup. Finally,
chance could play a role, particularly given the large number of associations examined and
sparse data for many analyses. However, in the four studies with large sample sizes
(N>=1000) for XRCC1 399 ever-never smoking, ORzs ranged from 1.0 (0.8, 1.2) to 1.6 (1.2,
2.0), while ORz was essentially null across the four large studies that examined XPD 194
ever-never smoking [ORzs=0.9, 1.0, 1.1 and 1.1]. Further, the magnitudes of ORz differed
across smoking status and amount for XRCC1 399 (3 populations) but not for XRCC1 194
(1 population). This large-sample sensitivity analysis is consistent with the overall
interpretation of ORz’s population-specificity for each SNP, rather than chance alone driving
the heterogeneity among studies.
Implications for stand-alone case-only studies
Z is a measure of the magnitude of bias in the COR. If Z=1, the case-only estimate of
interaction is not biased by genotype-environment association in the underlying population
(65). Commonly, this assumption is assessed in control data from a small number of outside
studies, using significance testing. Significance testing alone is not sufficient for assessment
of potential bias (76). Rarely is Z estimated and/or adjusted for, analogous to other forms of
bias such as confounding.
Results from this project illustrate some of the pitfalls of this approach. For instance, for
XRCC1 399 ever-never smoking, 18 of the 21 included studies have estimates that are not
statistically significantly different than the null value of 1.0. Considering any of these in a
statistical significance testing framework would lead to the conclusion that the independence
assumption was valid; therefore a case-only study estimate of interaction would not be
biased, at least from independence assumption violation. However, the range of ORzs for
these 18 studies is 0.7–1.6, many with wide CIs, indicating the substantial range of potential
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bias of the effect estimate. Given that different conclusions can be drawn from subsets of
smoking behavior and that less than half of the studies that collect control genotype and
smoking information present it in publications, this ever-never approach seems
inappropriate.
In the estimation framework, results from this project demonstrate the difficulty of using
ancillary data to assess the independence assumption. Even when the Cochran’s Q p-value is
high, such as for XRCC1 399 current-not current smoking (p=0.4), point estimates of ORz
can vary as much as 5-fold [2.1(1.1, 3.9) for African Americans (27) to 0.4(0.1, 1.2) (77)].
Without further information that certain study characteristics might be influential, there is no
good way to decide which of the available ancillary control groups might best represent the
underlying (unmeasured) population for a proposed case-only study. Further, it is necessary
to do a broad literature search to even to be aware of the possible values of ORz and range of
bias in the COR. Additionally, since both summary estimates and individual study estimates
vary across smoking categories, it is important that the independence assumption be
evaluated for all smoking categories that will be used in the case-only analyses. For
investigations of smoking amount, it will be difficult for many SNPs to locate enough
published control group data to even assess the possible range of the magnitude of bias.
This study has several strengths. Using a comprehensive search strategy in collaboration
with information specialists increased power to detect and investigate heterogeneity between
studies. Sample size was large for smoking status analyses and relatively large for XRCC1
399 and XPD 751 PY analyses. There were sufficient data for many studies to compare ORz
for smoking status and amount within studies, and by smoking category across multiple
SNPs. However, of the searched studies that collected the appropriate information only
about 1/3 presented it such that it could be abstracted for meta-analysis, limiting sample
size, especially for measures of smoking amount.
Only unadjusted odds ratios could be calculated so study estimates may have been
confounded. Although some study characteristics could be determined accurately from
articles, others were more likely to be misclassified. In particular, average age of study
participants was difficult to determine. However, the fact that age was not a central study
feature for any of the studies makes it likely that misclassification is non-differential with
respect to smoking and genotype. Several potentially informative study characteristics could
not be examined because too few articles presented the relevant information using the same
metric. In particular, response rates, which may vary by smoking behavior and family/
personal history of cancer (78–81), and control group exclusion criteria, were presented very
differently. Only two of the 12 articles with multi-ethnic study populations presented data
stratified by ethnicity, complicating interpretation of HWE p-value, ethnicity and MAF as
study characteristics. Few studies presented enough control group information to examine
multiple measures of smoking in the same study population.
This systematic review of control-group associations between smoking and widely studied
polymorphisms in DNA repair genes was conducted to accomplish several objectives. The
overarching goal was to enable investigators to make more effective use of ancillary data to
evaluate the independence assumption prior to launching a stand-alone case-only study.
Results from this study suggest that the independence assumption is frequently violated and
caution is warranted before proceeding with any case-only interaction analysis. At a
minimum, the independence assumption should be more rigorously evaluated than is often
done. For a case-only analysis of a case-control study, separate ORzs should be calculated
for each anticipated COR in the relevant subgroup before proceeding. Evaluation of the
independence assumption for a proposed stand-alone case-only study should include,
whenever possible, results from studies similar to the current study, relevant literature
Hodgson et al. Page 9













reviews, and a thorough search for individual studies with control or cohort data to ascertain
at least the range of ORzs, both overall and in relevant subgroups. Finally, it serves as a
reminder that in the traditional case-control study, interaction is a contrast between control-
only association and case-only association, and interaction can be driven by unanticipated
associations in controls.
Evaluation of the independence assumption for case-only interaction studies would be
greatly improved with more transparency and finer detail in published articles. This could
perhaps be accomplished by expanding supplementary online tables to include selected joint
genotype-smoking distributions in non-case groups. If it could reliably be shown that Z=1
across individual studies, better use could be made of data pooling from control groups and
cohorts for selected SNPs and exposures, especially where individual level data on potential
confounders can be provided. However, despite the current emphasis on pooling controls,
our results indicate that investigators should not proceed with case-only studies without
rigorously evaluating the independence assumption in individual studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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